"I don't want to do business at all because it is a national security threat," Trump told reporters.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
Coinbase security chief Philip Martin explains, "Possession of a key is possession of your currency. What that means is that you can't revoke a cryptocurrency key, if that key...Technologyread more
transfusion business - sources@
* Fresenius has hired Goldman Sachs for potential sale - sources
* Fresenius, Goldman decline to comment (Updates with background, no comment from Goldman)
FRANKFURT, May 10 (Reuters) - Fresenius has approached potential suitors about the sale of its blood transfusion business, two people with knowledge of the matter said on Friday.
Fresenius has hired Goldman Sachs to explore the sale, the people said.
Fresenius and Goldman declined to comment.
Fresenius Chief Executive Officer Stephan Sturm said in February the company was evaluating all options for its transfusion and cell therapy unit, and that it would be a better fit for a company more focused on the business.
Earlier this month, he said Fresenius was making good progress in the process.
The Frankfurter Allgemeine Zeitung first reported Friday's development. (Reporting by Arno Schuetze and Ludwig Burger; Writing by Tom Sims; Editing by Mark Potter)